Goldman Sachs
ALLO icon

Goldman Sachs’s Allogene Therapeutics ALLO Stock Holding History

Goldman Sachs’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-42,800
Closed -$1.61M – 5461
2020
Q3 		$1.61M Hold
42,800
– – ﹤0.01% 3722
2020
Q2 		$1.83M Buy
+42,800
New +$1.55M ﹤0.01% 3518

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ALLO Position: Q1 2026 in Review

Goldman Sachs increased its Allogene Therapeutics (ALLO) stake by 21% in Q1 2026, buying an estimated $956K and bringing the position to 2,766,244 shares worth $6.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

Goldman Sachs first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $50.9M in Q3 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Goldman Sachs held 2,766,244 shares of Allogene Therapeutics worth $6.75M as of Q1 2026.
  • Goldman Sachs bought 476,786 Allogene Therapeutics shares in Q1 2026, an estimated $956K.
  • Allogene Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3409 holding.
  • Goldman Sachs first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Goldman Sachs's Allogene Therapeutics position peaked at $50.9M in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.